PMID- 28060723
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20231112
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 5
DP  - 2017 Jan 31
TI  - The effect of androgen receptor expression on clinical characterization of 
      metastatic breast cancer.
PG  - 8693-8706
LID - 10.18632/oncotarget.14414 [doi]
AB  - In breast cancer (BC), androgen receptor (AR) expression is related to estrogen 
      receptor (ER) and/or progesterone receptor (PgR) expression. AR expression is an 
      indicator of good prognosis in breast cancer regardless of hormone receptor (HR) 
      status. In this study, we evaluated the effect of AR-related gene expression on 
      clinical characterization of metastatic BC. We performed RNA-Seq to evaluate gene 
      expression using mRNA extracted from 37 patients with metastatic BC. Intrinsic 
      subtype prediction, analysis of differential gene expression, and gene set 
      enrichment pathway analysis were then performed. Metastatic BCs were categorized 
      into three subgroups based on AR, ER, PgR, and HER2 expression. According to this 
      subcategorization, 70 genes including AR, ER, and HER2 were differentially 
      expressed among the three groups. In gene set enrichment pathway analysis, the 
      low AR group was associated with the cell cycle pathway, whereas mammalian target 
      of rapamycin (mTOR) pathways was prevalent in the high ER and AR group. In 
      survival analysis, a higher level of AR expression correlated with prolonged 
      overall survival in metastatic BC (high expression vs. low expression, median OS 
      53.1 vs. 27.2 months, p=.001). In conclusion, we propose that AR and AR-related 
      gene expression could be utilized to predict the prognosis of metastatic BC and 
      thus may be useful in treatment planning for refractory BC.
FAU - Kim, Ji-Yeon
AU  - Kim JY
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Seoul 06351, Korea.
FAU - Park, Kyunghee
AU  - Park K
AD  - Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
FAU - Lee, Eunjin
AU  - Lee E
AD  - Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
FAU - Jung, Hae Hyun
AU  - Jung HH
AD  - Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan 
      University School of Medicine, Seoul 06351, Korea.
FAU - Ahn, Jin Seok
AU  - Ahn JS
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Seoul 06351, Korea.
FAU - Im, Young-Hyuck
AU  - Im YH
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Seoul 06351, Korea.
AD  - Biomedical Research Institute, Samsung Medical Center, Seoul 06351, Korea.
FAU - Park, Woong-Yang
AU  - Park WY
AD  - Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
AD  - Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, 
      Seoul 06351, Korea.
FAU - Park, Yeon Hee
AU  - Park YH
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Seoul 06351, Korea.
AD  - Biomedical Research Institute, Samsung Medical Center, Seoul 06351, Korea.
AD  - Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan 
      University School of Medicine, Seoul 06351, Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (AR protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/analysis/*genetics
MH  - Breast Neoplasms/*genetics/mortality/pathology/therapy
MH  - Cell Movement/*genetics
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - RNA, Messenger/*genetics
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Androgen/*genetics
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
MH  - Risk Factors
MH  - Sequence Analysis, RNA
MH  - Signal Transduction/genetics
MH  - Time Factors
MH  - Transcriptome
PMC - PMC5352433
OTO - NOTNLM
OT  - RNA-Seq
OT  - androgen receptor (AR)
OT  - metastatic breast cancer
OT  - prognosis
COIS- CONFLICTS OF INTEREST The authors have no potential conflicts of interest to 
      declare.
EDAT- 2017/01/07 06:00
MHDA- 2018/02/27 06:00
PMCR- 2017/01/31
CRDT- 2017/01/07 06:00
PHST- 2016/05/20 00:00 [received]
PHST- 2016/12/05 00:00 [accepted]
PHST- 2017/01/07 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2017/01/07 06:00 [entrez]
PHST- 2017/01/31 00:00 [pmc-release]
AID - 14414 [pii]
AID - 10.18632/oncotarget.14414 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.